You are here
Professor Mimi Tang
Professor Mimi Tang has an international and national profile in the field of allergic and immune deficiency disorders. She has shown strong intellectual leadership and contribution to this field of research, evidenced by her participation on relevant international and national expert and peer review committees and contributions to health policy.
Professor Tang currently sits on a number of national and international expert committees for professional specialist societies, including the Australasian Society of Clinical Immunology and Allergy (ASCIA), the American Academy of Allergy Asthma and Immunology (AAAAI), and was a Board Director of the World Allergy Organisation. She has provided consultant services to the pharmaceutical industry and sat on Industry Medical and Scientific Advisory Boards (Immunology). She supports patient groups and is a member of the Medical Advisory Board of Allergy and Anaphylaxis Australia.
Professor Tang has more than 25 years' experience in the investigation of basic immunological mechanisms underlying allergic disease pathogenesis, and correlation of mechanistic studies with clinical outcomes. She has worked in the field of probiotics, prebiotics and gut microbiota for the past 15 years and has expertise in the investigation of gut microbiota changes in allergic disease. She is a leader in the field of primary immune deficiency in the Asia Pacific region. In addition, she has more than 15 years clinical trials experience, both as principle investigator on investigator led randomised trials and as co-investigator on international multicentre randomised trials.
Over the course of her career, Professor Tang has been awarded research grants totalling in excess of $45 million ($39 million peer reviewed) and has authored over 350 peer reviewed journal articles, invited reviews, and book chapters.
Professor Tang has demonstrated an ongoing and continued involvement in teaching undergraduate and postgraduate University of Melbourne students, and in supervision of advanced trainees in specialist Immunology Allergy physician training.
- 1995: International Fellowship Award, Pharmacia
- 1995: Research Fellowship Award, Allen and Hanbury's Research Institute ** First time awarded to a Non-US Citizen
- 1996: Presidents Grant-in-Aid Award, American Academy of Allergy Asthma and Immunology ** First time awarded to a Non-US Citizen
- 2009: Most Appropriate Care Award, Victorian Public Healthcare, Department of Health
- 1998: Clinical Investigator Award, Australian Society of Clinical Immunology Allergy
- 1994: Fulbright Fellowship (deferred), Australian-American Fulbright Commission
- 1991 - 1994: Postgraduate Research Scholarship, National Health & Medical Research Council
- 1993: JJ Billings Fellowship, Royal Australasian College of Physicians
- Nestle Travel Scholarship, Australian College of Paediatrics 1993
- 1992: Young Investigator Award, Australian Society of Clinical Immunology Allergy
Professor Tang's research is currently focused on investigating immunological mechanisms underlying the development of allergic disorders and conducting multicentre randomized controlled clinical trials evaluating novel treatment interventions for prevention and treatment of food allergies. She is also co-investigator on a number of longitudinal cohort studies including the Barwon Infant Study, HealthNuts and SchoolNuts.
• PPOIT-003 study (Probiotic and Peanut Oral Immunotherapy) - This project evaluates a novel approach to treatment of peanut allergy, with the aim of inducing sustained unresponsiveness to peanut. Immune mechanisms of sustained unresponsiveness are also investigated. Recruitment for this study has closed. The study is expected to be completed at the end of 2020.
• (PEAT study)(Probiotic Egg Allergen Immunotherapy for Treatment of Egg Allergy) - This project is studying egg oral immunotherapy in combination with probiotics to see if it is effective in treating children with egg allergy
• PrEMO study (Probiotic and Egg or Milk Oral Immunotherapy) - An open-label study of probiotic and hen’s egg or cow’s milk oral immunotherapy to assess the rate of sustained unresponsiveness and desensitisation following 18 months of probiotic egg oral immunotherapy (OIT) or probiotic milk OIT
• (Barwon Infant Study)- The Barwon Infant Study (BIS) is a major population-based birth cohort study being conducted by the Child Health Research Unit (CHRU) at Barwon Health in collaboration with the Murdoch Children’s Research Institute (MCRI) and Deakin University. The aim of the BIS is to investigate postnatal microbial experience, immune programming and allergic disease risk
• (HealthNuts) - This study of 5,300 children is the world's first comprehensive population-based study of food allergy with objective measurement of true food allergy, enabling a better understand the natural history of allergic disorders including food allergy, asthma, eczema and hay fever and the risk factors for developing these conditions in childhood. The study will have important implications for clinical guidelines and public health policy
• (SchoolNuts) - A population-based study of the prevalence of challenge-proven food allergy and predictors of severe adverse reactions to food in early adolescence. This project aims to identify the lifestyle factors which are common to children suffering from food allergy, assess the impact of food allergy on risk of asthma and severity and identify factors which are likely to modify control of food allergy and asthma
• (VITALITY) -The aims of this study are to see the relationship between food allergy, vitamin D and immune function in infants
• (Pebbles Study) - A randomised controlled trial to prevent eczema, food allergy and sensitisation using a topical skin barrier improvement strategy
• CRE in Eradicating Food Allergy: Prevention, Cure and Reducing Adverse Events – The aim of this study is to eradicate food allergy through improved prevention and cure, supported by evidence generated by a collaborative network of research. An additional aim is to help prevent children with food allergy having anaphylaxis through improved public health policy and clinical pathways.
Recent Key publications:
1. Tang MLK, Allen KJ. "Kids Food Allergies for Dummies". Wiley Publishing, Australia 2012.
2. Tang MLK, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, Licciardi P, Burks W, Donath S. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. Journal of Allergy and Clinical Immunology. 2015;135(3):737-44.
3. Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK, Burks W, Donath S, Orsini F, Tey D, Robinson M, Su EL. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child and Adolescent Health. 2017;1(2):97-105.
4. Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, the PPOIT Study Team. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy: European Journal of Allergy and Clinical Immunology. 2018;73(3):560-8.
5. Hiscock H, Perera P, Danchin MH, Sung V, Lee K, Stival C, Peat R, Molloy J, Selvakumaran S, Tang MLK. Improving timely access to food allergy care: A pragmatic controlled trial. Allergy: European Journal of Allergy and Clinical Immunology. 2020;75(6):1449-1453.
6. Tang MLK, Lozinsky AC, Loke P. Peanut Oral Immunotherapy: State of the Art (Review). Immunology and Allergy Clinics of North America. 2020;40(1):97-110.
- National Health and Medical Research Council
- Murdoch Childrens Research Institute
- RCH foundation
- Prota therapeutics
- Ilhan Food Allergy Foundation (Australian Food Allergy Foundation)
- Bayer Australia